Laryngeal papillomatosis

Last updated
Laryngeal papillomatosis
Other namesAdult papillomatosis, Juvenile papillomatosis, Recurrent respiratory papillomatosis (RRP), Squamous cell papillomatosis, Nonkeratinized papillomatosis
CT tracheal papillomatosis volume.png
Volumetric CT rendering of multiple tracheal papilloma (arrow)
Specialty Otorhinolaryngology   OOjs UI icon edit-ltr-progressive.svg
Complications Squamous cell carcinoma
CausesHPV infection

Laryngeal papillomatosis, also known as recurrent respiratory papillomatosis (RRP) or glottal papillomatosis, is a rare medical condition in which benign tumors (papilloma) form along the aerodigestive tract. [1] [2] There are two variants based on the age of onset: juvenile and adult laryngeal papillomatosis. [3] The tumors are caused by human papillomavirus (HPV) infection of the throat. The tumors may lead to narrowing of the airway, which may cause vocal changes or airway obstruction. [4] [5] Laryngeal papillomatosis is initially diagnosed through indirect laryngoscopy upon observation of growths on the larynx and can be confirmed through a biopsy. [6] [7] [8] Treatment for laryngeal papillomatosis aims to remove the papillomas and limit their recurrence. [9] Due to the recurrent nature of the virus, repeated treatments usually are needed. [7] [9] [2] [10] Laryngeal papillomatosis is primarily treated surgically, though supplemental nonsurgical and/or medical treatments may be considered in some cases. [7] [10] The evolution of laryngeal papillomatosis is highly variable. [4] [1] Though total recovery may be observed, it is often persistent despite treatment. [11] [8] [1] The number of new cases of laryngeal papillomatosis cases is approximately 4.3 cases per 100,000 children and 1.8 cases per 100,000 adults annually. [1] [6] [7] [12]

Contents

Signs and symptoms

A common symptom of laryngeal papillomatosis is a change in voice quality. More specifically, hoarseness is observed. [4] [5] As a consequence of the narrowing of the laryngeal or tracheal parts of the airway, shortness of breath, chronic cough and stridor (i.e. noisy breathing which can sound like a whistle or a snore), can be present. [4] [5] As the disease progresses, occurrence of secondary symptoms such as dysphagia, pneumonia, acute respiratory distress syndrome, failure to thrive, and recurrent upper respiratory infections can be diagnosed. [4] [5] The risk of laryngeal papillomatosis spreading to the lungs is higher in the juvenile-onset than the adult-onset. [3] In children, symptoms are usually more severe and often mistaken for manifestations of other diseases such as asthma, croup or bronchitis. Therefore, diagnosis is usually delayed. [8] [5]

Cause

Laryngeal papillomatosis is caused by human papillomavirus (HPV) infection, most frequently types 6 and 11, [13] although genotypes 16, 18, 31, and 33 have also been implicated. [7] HPV-11 is associated with more aggressive forms of papillomatosis, which may involve more distal parts of the tracheobronchial tree. [7] The mode of viral inoculation is hypothesized to vary according to age of disease onset. [13] [14] The presence of HPV in the respiratory tract does not necessarily result in the development of laryngeal papillomatosis. Other factors that could be involved include immunodeficiency or other similar infections. For example, laryngeal papillomatosis may become more aggressive due to the presence of certain viruses (e.g., herpes simplex virus, Epstein–Barr virus). [2]

The disease occurs in two forms, juvenile and adult papillomatosis, based on whether it develops before or after 20 years of age. [1] [7] The juvenile form is generally transmitted through contact with a mother's infected vaginal canal during childbirth. [14] Less is known about transmission in the adult form of this disease, though oral sex has been implicated as a potential mode of transmission. [13] [14] However, it is uncertain whether oral sex would directly transmit the virus [14] or activate the dormant virus that was transmitted at childbirth. [14] [13]

In general, physicians are unsure why only certain people who have been exposed to the HPV types implicated in the disease develop laryngeal papillomatosis. In the case of the juvenile form of the disease, the likelihood of a child born of an infected mother developing laryngeal papillomatosis is low (between 1 in 231 to 1 in 400), [15] even if the mother's infection is active. [13] Risk factors for a higher likelihood of transmission at childbirth include the first birth, vaginal birth, and teenaged mother. [14] [13]

Three major risk factors affect the acquisition of the juvenile variant. These include: [16]

Diagnosis

Laryngeal papillomatosis can be diagnosed through visualization of the lesions using one of several indirect laryngoscopy procedures. [6] [8] In indirect laryngoscopy, the tongue is pulled forward and a laryngeal mirror or a rigid scope is passed through the mouth to examine the larynx. [12] [6] Another variation of indirect laryngoscopy involves passing a flexible scope, known as a fiberscope or endoscope, through the nose and into the throat to visualize the larynx from above. [12] [8] This procedure is also called flexible fiberoptic laryngoscopy. [12]

The appearance of papillomas has been described as multiple or rarely, single, white growths with a lumpy texture similar to cauliflower. [12] [7] Papillomas usually present in the larynx, especially on the vocal folds and in the space above the vocal folds called the ventricles. [17] [18] [1] They can spread to other parts of the larynx and throughout the aerodigestive tract, from the mouth to the lower respiratory tract. [1] [7] [17] Spread to regions beyond the larynx is more common in children than adults. [17] Growths tend to be located at normal junctions in squamous and ciliated epithelium or at tissue junctions arising from injury. [1] [17] [18]

A confirmatory diagnosis of laryngeal papillomatosis can only be obtained through a biopsy, involving microscopic examination and HPV testing of a sample of the growth. [7] [6] Biopsy samples are collected under general anesthesia, either through direct laryngoscopy or fiberoptic bronchoscopy. [6] [7]

Prevention

Little is known in terms of effective means of prevention, if the mother is infected with HPV. (HPV vaccination can prevent these infections in the mother, and thereby eliminate the possibility of the virus infecting the baby. [19] ) Due to the low likelihood of transmission even from an infected mother, it is not recommended to expose the mother and child to the additional risks of caesarean section to prevent the transmission of this disease during vaginal childbirth. [13] Opting for a caesarean section does not guarantee that transmission will not still occur. [14]

Treatment

As of 2014, there was no permanent cure for laryngeal papillomatosis, and treatment options aimed to remove and limit the recurrence of the papillomas. [9] Repeated treatments are often needed because of the recurrent nature of the virus, especially for children, as the juvenile form of laryngeal papillomatosis often triggers more aggressive relapses than the adult form. [9] [2] [7] [10] Between recurrences, voice therapy may be used to restore or maintain the person's voice function. [12]

Surgery

The first line of treatment is surgery to remove papillomas. [7] [10] Typically performed using a laryngeal endoscopy, surgery can protect intact tissues and the individual's voice, as well as ensure that the airway remains unobstructed by the disease. [2] However, surgery does not prevent recurrences, and can lead to a number of serious complications. [9] [7] [10] Laser technology, and carbon dioxide laser surgery in particular, has been used since the 1970s for the removal of papillomas; however, laser surgery is not without its risks, and has been associated with a higher occurrence of respiratory tract burns, stenosis, severe laryngeal scarring, and tracheoesophagyeal fistulae. [9] [2] [7] [10] Tracheotomies are offered for the most aggressive cases, where multiple debulking surgery failures have led to airways being compromised. [2] [7] The tracheotomies use breathing tubes to reroute air around the affected area, thereby restoring the person's breathing function. Although this intervention is usually temporary, some people must use the tube indefinitely. [8] This method should be avoided if at all possible, since the breathing tube may serve as a conduit for spread of the disease as far down as the tracheobronchial tree. [2] [7]

A microdebrider is a tool that can suction tissue into a blade, which then cuts the tissue. Microdebriders are gradually replacing laser technology as the treatment of choice for laryngeal papillomatosis, due to their ability to selectively suction papillomas while relatively sparing unaffected tissue. [2] [10] In addition to the lower risk of complications, microdebrider surgery also is reportedly less expensive, less time-consuming, and more likely to give the person a better voice quality than the traditional laser surgery approaches. [10]

Nonsurgical adjuvant treatment

For about 20% of people, surgery is not sufficient to control their laryngeal papillomatosis, and additional nonsurgical and/or medical treatments are necessary. [7] As of 2015, these treatments alone are not sufficient to cure laryngeal papillomatosis, and can only be considered supplemental to surgery. [2] Some varieties of nonsurgical treatments include interferon, antiviral drugs (especially cidofovir, but also ribavirin and acyclovir), and photodynamic therapy. [9] [2] [7] [10] [12] The monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab, has shown promising result as an adjuvant therapy in the management of recurrent respiratory papillomatosis. [20] [21]

Although vaccines are normally used to prevent infections from happening, HPV vaccines can be used therapeutically (after the infection has occurred). [22] [23] For most patients, the HPV vaccine significantly increases the length of time needed between surgeries. [19] [22] [23]

Prognosis

The evolution of laryngeal papillomatosis is highly unpredictable and is characterized by modulation of its severity and variable rate of progression across individuals. [4] [1] While instances of total recovery are observed, the condition is often persistent and lesions can reappear even after treatment. [8] [1] [11] Factors that might affect the clinical course of the condition include: the HPV genotype, the age at onset, the elapsed time between the diagnosis and first treatment in addition to previous medical procedures. [7] [17] [1] Other factors, albeit controversial, such as smoking or the presence of gastroesophageal reflux disease might also play a role in the progression of the disease. [17] [3]

The papillomas can travel past the larynx and infect extralaryngeal sites. [4] In more aggressive cases, infection of the lungs can occur with progressive airway obstruction. [4] [5] Although rare (less than 1% of people with laryngeal papillomatosis), transformation from a benign form to a malignant form is also observed. [4] [5] Death can result from these complications (morbidity rate is around 1–2%). [4]

Epidemiology

Laryngeal papillomatosis is a rare disease with a bimodal distribution based on age of incidence. [1] The incidence, or number of new cases, of laryngeal papillomatosis cases is at approximately 4.3 cases per 100,000 children and 1.8 cases per 100,000 adults annually. [7] [6] [12] [1] The incidence of laryngeal papillomatosis in children peaks before the age of 5, though the term juvenile papillomatosis refers to all cases occurring before the age of 20. [1] [7] The incidence of adult laryngeal papillomatosis, which has an onset after the age of 20, peaks between the ages of 20 and 40. [7] [1] While there are no gender differences in the incidence of laryngeal papillomatosis in children, adult laryngeal papillomatosis occurs more frequently in males than in females. [7] [17] [1] The incidence of laryngeal papillomatosis also varies according to factors such as socioeconomic status, such that higher rates are observed in groups having a lower socioeconomic status. [7]

Costs

Because of its relative commonness and the cost of treatments, more money is spent on treating RRP than on any other benign airway tumor. [22]

Research

As of 2015, use of the measles–mumps–rubella vaccine to reduce rate of recurrences had been investigated, but had not yielded significant results. [2]

See also

Related Research Articles

<span class="mw-page-title-main">Wart</span> Small, rough growth resembling a cauliflower or a solid blister

Warts are non-cancerous viral growths usually occurring on the hands and feet but can also affect other locations, such as the genitals or face. One or many warts may appear. They are distinguished from cancerous tumors as they are caused by a viral infection, such as a human papillomavirus, rather than a cancerous growth.

<span class="mw-page-title-main">Cervical cancer</span> Cancer arising from the cervix

Cervical cancer is a cancer arising from the cervix or in the any layer of the wall of the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.

<span class="mw-page-title-main">Human papillomavirus infection</span> Human disease

Human papillomavirus infection is caused by a DNA virus from the Papillomaviridae family. Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. In some cases, an HPV infection persists and results in either warts or precancerous lesions. These lesions, depending on the site affected, increase the risk of cancer of the cervix, vulva, vagina, penis, anus, mouth, tonsils, or throat. Nearly all cervical cancer is due to HPV, and two strains – HPV16 and HPV18 – account for 70% of all cases. HPV16 is responsible for almost 90% of HPV-positive oropharyngeal cancers. Between 60% and 90% of the other cancers listed above are also linked to HPV. HPV6 and HPV11 are common causes of genital warts and laryngeal papillomatosis.

<span class="mw-page-title-main">Genital wart</span> Sexually transmitted infection caused by certain types of human papillomaviruses

Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus (HPV). They may be flat or project out from the surface of the skin, and their color may vary; brownish, white, pale yellow, pinkish-red, or gray. There may be a few individual warts or several, either in a cluster or merged together to look cauliflower-shaped. They can be itchy and feel burning. Usually they cause few symptoms, but can occasionally be painful. Typically they appear one to eight months following exposure. Warts are the most easily recognized symptom of genital HPV infection.

<span class="mw-page-title-main">Laryngeal cancer</span> Medical condition

Laryngeal cancer or throat cancer is a kind of cancer that can develop in any part of the larynx. It is typically a squamous-cell carcinoma, reflecting its origin from the epithelium of the larynx.

<span class="mw-page-title-main">Laryngitis</span> Medical condition

Laryngitis is inflammation of the larynx. Symptoms often include a hoarse voice and may include fever, cough, pain in the front of the neck, and trouble swallowing. Typically, these last under two weeks.

<span class="mw-page-title-main">Anal cancer</span> Medical condition

Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract. Symptoms may include bleeding from the anus or a lump near the anus. Other symptoms may include pain, itchiness, or discharge from the anus. A change in bowel movements may also occur.

<span class="mw-page-title-main">Head and neck cancer</span> Cancer arises in the head or neck region

Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary glands, nose, sinuses, or skin of the face. The most common types of head and neck cancer occur in the lips, mouth, and larynx. Symptoms predominantly include a sore that does not heal or a change in the voice. In those with advanced disease, there may be unusual bleeding, facial pain, numbness or swelling, and visible lumps on the outside of the neck or oral cavity. Given the location of these cancers, it is possible for an afflicted individual to experience difficulty breathing.

<span class="mw-page-title-main">Laryngectomy</span> Surgical procedure

Laryngectomy is the removal of the larynx and separation of the airway from the mouth, nose and esophagus. In a total laryngectomy, the entire larynx is removed. In a partial laryngectomy, only a portion of the larynx is removed. Following the procedure, the person breathes through an opening in the neck known as a stoma. This procedure is usually performed by an ENT surgeon in cases of laryngeal cancer. Many cases of laryngeal cancer are treated with more conservative methods. A laryngectomy is performed when these treatments fail to conserve the larynx or when the cancer has progressed such that normal functioning would be prevented. Laryngectomies are also performed on individuals with other types of head and neck cancer. Less invasive partial laryngectomies, including tracheal shaves and feminization laryngoplasty may also be performed on transgender women and other female or non-binary identified individuals to feminize the larynx and/or voice. Post-laryngectomy rehabilitation includes voice restoration, oral feeding and more recently, smell and taste rehabilitation. An individual's quality of life can be affected post-surgery.

<span class="mw-page-title-main">Recurrent laryngeal nerve</span> Nerve in the human body

The recurrent laryngeal nerve (RLN) is a branch of the vagus nerve that supplies all the intrinsic muscles of the larynx, with the exception of the cricothyroid muscles. There are two recurrent laryngeal nerves, right and left. The right and left nerves are not symmetrical, with the left nerve looping under the aortic arch, and the right nerve looping under the right subclavian artery then traveling upwards. They both travel alongside the trachea. Additionally, the nerves are among the few nerves that follow a recurrent course, moving in the opposite direction to the nerve they branch from, a fact from which they gain their name.

<span class="mw-page-title-main">Papilloma</span> Medical condition

A papilloma is a benign epithelial tumor growing exophytically in nipple-like and often finger-like fronds. In this context, papilla refers to the projection created by the tumor, not a tumor on an already existing papilla.

Vocal cord paresis, also known as recurrent laryngeal nerve paralysis or vocal fold paralysis, is an injury to one or both recurrent laryngeal nerves (RLNs), which control all intrinsic muscles of the larynx except for the cricothyroid muscle. The RLN is important for speaking, breathing and swallowing.

<span class="mw-page-title-main">Subglottic stenosis</span> Medical condition

Subglottic stenosis is a congenital or acquired narrowing of the subglottic airway. It can be congenital, acquired, iatrogenic, or very rarely, idiopathic. It is defined as the narrowing of the portion of the airway that lies between the vocal cords and the lower part of the cricoid cartilage. In a normal infant, the subglottic airway is 4.5-5.5 millimeters wide, while in a premature infant, the normal width is 3.5 millimeters. Subglottic stenosis is defined as a diameter of under 4 millimeters in an infant. Acquired cases are more common than congenital cases due to prolonged intubation being introduced in the 1960s. It is most frequently caused by certain medical procedures or external trauma, although infections and systemic diseases can also cause it.

Vaginal cancer is an extraordinarily rare form of cancer that develops in the tissue of the vagina. Primary vaginal cancer originates from the vaginal tissue – most frequently squamous cell carcinoma, but primary vaginal adenocarcinoma, sarcoma, and melanoma have also been reported – while secondary vaginal cancer involves the metastasis of a cancer that originated in a different part of the body. Secondary vaginal cancer is more common. Signs of vaginal cancer may include abnormal vaginal bleeding, dysuria, tenesmus, or pelvic pain, though as many as 20% of women diagnosed with vaginal cancer are asymptomatic at the time of diagnosis. Vaginal cancer occurs more frequently in women over age 50, and the mean age of diagnosis of vaginal cancer is 60 years. It often can be cured if found and treated in early stages. Surgery alone or surgery combined with pelvic radiation is typically used to treat vaginal cancer.

<span class="mw-page-title-main">Squamous cell papilloma</span> Medical condition

A squamous cell papilloma is a generally benign papilloma that arises from the stratified squamous epithelium of the skin, lip, oral cavity, tongue, pharynx, larynx, esophagus, cervix, vagina or anal canal. Squamous cell papillomas are typically associated with human papillomavirus (HPV) while sometimes the cause is unknown.

<span class="mw-page-title-main">Laryngopharyngeal reflux</span> Medical condition

Laryngopharyngeal reflux (LPR) or laryngopharyngeal reflux disease (LPRD) is the retrograde flow of gastric contents into the larynx, oropharynx and/or the nasopharynx. LPR causes respiratory symptoms such as cough and wheezing and is often associated with head and neck complaints such as dysphonia, globus pharyngis, and dysphagia. LPR may play a role in other diseases, such as sinusitis, otitis media, and rhinitis, and can be a comorbidity of asthma. While LPR is commonly used interchangeably with gastroesophageal reflux disease (GERD), it presents with a different pathophysiology.

HspE7 is an investigational therapeutic vaccine candidate being developed by Nventa Biopharmaceuticals for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV). HspE7 uses recombinant DNA technology to covalently fuse a heat shock protein (Hsp) to a target antigen, thereby stimulating cellular immune system responses to specific diseases. HspE7 is a patented construct consisting of the HPV Type 16 E7 protein and heat shock protein 65 (Hsp65) and is currently the only candidate using Hsp technology to target the over 20 million Americans already infected with HPV.

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

<span class="mw-page-title-main">Bettie Steinberg</span> American microbiologist

Bettie M. Steinberg holds multiple positions within Northwell Health: Chief Scientific Officer for The Feinstein Institute for Medical Research, Dean of the Elmezzi Graduate School of Molecular Medicine, and Chair of the Department of Molecular Medicine at the Hofstra Northwell School of Medicine in Hempstead, NY.

<span class="mw-page-title-main">Squamous cell carcinoma of the vagina</span> Medical condition

Squamous cell carcinoma of the vagina is a potentially invasive type of cancer that forms in the tissues of the vagina. Though uncommonly diagnosed, squamous cell cancer of the vagina (SCCV) is the most common type of vaginal cancer, accounting for 80-90% of cases as well as 2% of all gynecological cancers. SCCV forms in squamous cells, which are the thin, flat cells lining the vagina. SCCV initially spreads superficially within the vaginal wall and can slowly spread to invade other vaginal tissues. Because of its slow growth, this cancer may cause no symptoms, or it may present with signs like irregular bleeding, pain, or a vaginal mass. This carcinoma can metastasize to the lungs or less frequently to the liver, bone, or other sites. SCCV has many risk factors in common with cervical cancer and is similarly strongly associated with infection with oncogenic strains of human papillomavirus (HPV). Diagnosis of SCCV is done by pelvic exam and biopsy of the tissue. Treatment and prognosis will depend on the stage, location, and characteristics of the cancer.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 El-Naggar AK, Chan JK, Grandis JR, Takashi T, Slootweg PJ, eds. (2017). "Tumours of the Hypopharynx, Larynx, Trachea and Parapharyngeal Space". World Health Organization Classification of Head and Neck Tumours. Lyon: International Agency for Research on Cancer. pp. 93–95. ISBN   9789283224389. OCLC   990147303.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 Carifi M, Napolitano D, Morandi M, Dall'Olio D (2015). "Recurrent respiratory papillomatosis: current and future perspectives". Therapeutics and Clinical Risk Management. 11: 731–738. doi: 10.2147/TCRM.S81825 . PMC   4427257 . PMID   25999724.
  3. 1 2 3 Taliercio S, Cespedes M, Born H, Ruiz R, Roof S, Amin MR, Branski RC (January 2015). "Adult-onset recurrent respiratory papillomatosis: a review of disease pathogenesis and implications for patient counseling". JAMA Otolaryngology–Head & Neck Surgery. 141 (1): 78–83. doi:10.1001/jamaoto.2014.2826. PMID   25393901.
  4. 1 2 3 4 5 6 7 8 9 10 Mehta AC, Jain P, Prasoon G, Gildea TR (2016). Diseases of the central airways : a clinical guide. Springer. pp. 215–218. ISBN   9783319298283. OCLC   945577007.
  5. 1 2 3 4 5 6 7 Venkatesan NN, Pine HS, Underbrink MP (June 2012). "Recurrent respiratory papillomatosis". Otolaryngologic Clinics of North America. 45 (3): 671–694, viii–ix. doi:10.1016/j.otc.2012.03.006. PMC   3682415 . PMID   22588043.
  6. 1 2 3 4 5 6 7 Grimes J, Fagerberg K, Smith L, eds. (2014). "Laryngeal Papillomatosis". Sexually Transmitted Disease : An Encyclopedia of Diseases, Prevention, Treatment, and Issues. Greenwood. pp. 401–403. ISBN   9781440801341. OCLC   880530919.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. (May 2017). "Recurrent respiratory papillomatosis: A state-of-the-art review". Respiratory Medicine. 126: 116–121. doi: 10.1016/j.rmed.2017.03.030 . hdl: 10923/22484 . PMID   28427542.
  8. 1 2 3 4 5 6 7 "Recurrent Respiratory Papillomatosis or Laryngeal Papillomatosis". NIDCD. 2015-08-18. Retrieved 2017-10-21.
  9. 1 2 3 4 5 6 7 Alfano DM (2014). "Human papillomavirus laryngeal tracheal papillomatosis". Journal of Pediatric Health Care. 28 (5): 451–455. doi:10.1016/j.pedhc.2014.04.003. PMID   24882788.
  10. 1 2 3 4 5 6 7 8 9 Avelino MA, Zaiden TC, Gomes RO (September 2013). "Surgical treatment and adjuvant therapies of recurrent respiratory papillomatosis". Brazilian Journal of Otorhinolaryngology. 79 (5): 636–642. doi: 10.5935/1808-8694.20130114 . PMC   9442437 . PMID   24141682.
  11. 1 2 Drejet S, Halum S, Brigger M, Skopelja E, Parker NP (March 2017). "A Systematic Review". Otolaryngology–Head and Neck Surgery. 156 (3): 435–441. doi:10.1177/0194599816683384. PMID   28072562. S2CID   4406970.
  12. 1 2 3 4 5 6 7 8 Colton RH, Casper JK, Leonard R (2011). Understanding Voice Problems : A Physiological Perspective for Diagnosis and Treatment (4th ed.). Philadelphia, PA: Lippincott Williams & Wilkins. pp. 171–172, 224–228. ISBN   9781609138745. OCLC   660546194.
  13. 1 2 3 4 5 6 7 Larson DA, Derkay CS (June 2010). "Epidemiology of recurrent respiratory papillomatosis". APMIS. 118 (6–7): 450–454. doi: 10.1111/j.1600-0463.2010.02619.x . PMID   20553527. S2CID   193686.
  14. 1 2 3 4 5 6 7 Barnes L (2005). Pathology and genetics of head and neck tumours (PDF). IARC Press Lyon. pp. 144–145.
  15. ↑ Derkay CS, Wiatrak B (July 2008). "Recurrent respiratory papillomatosis: a review". The Laryngoscope. 118 (7): 1236–1247. doi:10.1097/MLG.0b013e31816a7135. PMID   18496162. S2CID   12467098.
  16. ↑ Niyibizi J, Rodier C, Wassef M, Trottier H (February 2014). "Risk factors for the development and severity of juvenile-onset recurrent respiratory papillomatosis: a systematic review". International Journal of Pediatric Otorhinolaryngology. 78 (2): 186–197. doi:10.1016/j.ijporl.2013.11.036. PMID   24367938.
  17. 1 2 3 4 5 6 7 Wenig BM, Fletcher CD (2013). "Tumors of the Upper Respiratory Tract". In Fletcher CD (ed.). Diagnostic Histopathology of Tumors (4th ed.). Philadelphia, PA: Saunders/Elsevier. pp. 92–98. ISBN   9781455737543. OCLC   846903109.
  18. 1 2 Grant DG, Mirchall MA, Bradley PJ (2010). "Surgery for Benign Tumors of the Adult Larynx". In Remacle M, Eckel HE (eds.). Surgery of Larynx and Trachea . Berlin: Springer-Verlag Berlin Heidelberg. pp.  91–112. ISBN   9783540791355. OCLC   567327912.
  19. 1 2 Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L (February 2018). "Current and future management of recurrent respiratory papillomatosis". Laryngoscope Investigative Otolaryngology. 3 (1): 22–34. doi:10.1002/lio2.132. PMC   5824106 . PMID   29492465.
  20. ↑ Mohr M, Schliemann C, Biermann C, Schmidt L-H, Kessler T, Schmidt J, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett. 2014 Nov;8(5):1912–8.
  21. ↑ Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014 Mar;123(3):214–21.
  22. 1 2 3 Derkay CS, Bluher AE (December 2018). "Recurrent respiratory papillomatosis: update 2018". Current Opinion in Otolaryngology & Head and Neck Surgery. 26 (6): 421–425. doi:10.1097/MOO.0000000000000490. PMID   30300210. S2CID   52947478.
  23. 1 2 Pham CT, Juhasz M, Sung CT, Mesinkovska NA (January 2020). "The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review". Journal of the American Academy of Dermatology. 82 (1): 202–212. doi:10.1016/j.jaad.2019.04.067. PMID   31085272. S2CID   155092723.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.